Premier Research Acquires Camargo Pharmaceutical Services

Premier Research has acquired Camargo Pharmaceutical Services based in Cincinnati, OH.

Premier Research is a provider of strategic and regulatory advisory services as well as clinical development services to the biotechnology, specialty pharma, and medical device industry. Camargo is a global strategy, regulatory, and commercial partner for emerging biopharma companies and has experience in complex development programs and accelerated approval pathways that leverages their expertise in areas such as oncology, pediatrics, rare disease, and 505(b)(2) product development.

This combination will expand and strengthen the product planning, development, and differentiation services that both companies have been offering to their diverse and innovative customers.

“We are confident in this transaction knowing that we now have a deeper bench of knowledge and expertise to support our clients in all phases of their product development,” said Sameena Sharif, president, Regulatory Professionals, a division of Premier Research. “Camargo’s recognized regulatory, non-clinical development, and patient-centric product differentiation services will strongly augment the strategic and development consulting services that we have been providing for over 25 years.”

Dan Duffy, CEO, Camargo, said, “Premier Research’s well-deserved reputation and strength in assisting its customers, particularly in rare disease and oncology, will help accelerate our combined growth in specialty pharma—an area that was recently bolstered by the acquisition of Paidion, a clinical research organization focused on the development of new pediatric and neonatal products.”

Ludo Reynders, CEO, Premier Research, said, “Camargo is a natural fit that will enable us to extend our commitment to helping customers answer the unmet needs of patients across a broad range of medical conditions. This transaction allows us to continually improve on product development consulting and study outcomes from early stage to commercialization. The impact of targeted clinical development and differentiation continues to be clear and increasingly positive for our people as well as our global community as we move into a post-pandemic era; we are delighted to be an active agent in its progress.”